CC
CYT

Cannell Capital’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Cannell Capital’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-19,684
Closed -$35.8K – 93
2023
Q1 		$35.8K Hold
19,684
– – 0.01% 76
2022
Q4 		$32.5K Hold
19,684
– – 0.01% 79
2022
Q3 		$38K Buy
19,684
+15,793
+406% +$41.2K 0.01% 79
2022
Q2 		$12K Buy
+3,891
New +$9.94K ﹤0.01% 72

Other funds holding CYT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.41M AUM 48.57% 1-Year Est. Return

Cannell Capital's CYT Position: Q2 2023 in Review

Cannell Capital sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q2 2023, closing a stake of 19,684 shares — an estimated $35.8K sold.

Cannell Capital first reported a position in CYT in Q2 2022 and held it in 4 quarters. The position peaked at $38K in Q3 2022. 39 funds tracked by Wall St. Rank hold CYT as of Q2 2023.

  • Cannell Capital reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Cannell Capital sold 19,684 Cyteir Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $35.8K.
  • Cannell Capital first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q2 2022 and held it in 4 quarters.
  • Cannell Capital's Cyteir Therapeutics, Inc. Common Stock position peaked at $38K in Q3 2022.
  • 39 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Cannell Capital's 13F filing for Q2 2023, filed 14 Aug 2023.